100s of titles, one news app for just $10 a month.
Dive Deeper:
IM Cannabis Reports Record First Quarter 2022 Financial Results, Revenues Increase 169% YoY To $23.6M
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), a medical and adult-use cannabis company with operations in Israel, Canada, and Germany,…
TerrAscend Reports First Quarter 2022 Financial Results, Net Sales Up To $49.7M
TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF), reported its financial results late Thursday for the first quarter ending March 31, 2022.
Organigram Q2 Fiscal 2022 Revenue Grows 117% YoY Primaraly Because Of This
Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI), the parent company of Organigram Inc., released its results for the second quarter ended…
Aurora Cannabis Reports Fiscal 2022 Q3 Results, Net Revenue $50.4M
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a Canadian cannabis company, announced its financial and operational results late Thursday for the…
One subscription that gives you access to news from hundreds of sites
MariMed Reports Strong Q1, Provides 2022 Financial Guidance
MariMed, Inc. (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results…
Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?
Aurora Cannabis Inc. (NASDAQ: ACB) reported financial and operational results late Thursday for the third quarter of fiscal 2022 ended March…
Get all your news in one place
Latest Business news:
Survivor, Bachelor in Paradise, Love Island: How Fiji is cashing in on reality TV favourites
Fiji is a small nation looking for big investment and it is working hard to make film and reality television…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
The Stats Guy: What does tourism in Australia look like now that travellers are returning?
The tourism sector is preparing for a comeback. So, what is the state of play in the sector and what…
Tech’s High-Flying Startup Scene Gets a Crushing Reality Check
Job cuts and a sour investment climate are hitting big companies like Stripe and Instacart, and may slam smaller ones…
Has crash in stablecoins slowed down sales in NFTs?
According to CrytoSlam data, so far in May, sales in NFTs stand at $2.4 billion with a total transaction of…
Fraud alert! AI identifies the four stages of a scam phone call
Australian researchers have used machine learning techniques to identify the typical four stages of fraudulent money-taking phone calls.
From analysis to good news, read the world’s best news in one place
Do Walmart and Target Have an Inventory Problem?
Ark Investing's Cathie Wood thinks so and this could be good for consumers, but maybe not investors at least in…
How an Energy Expert Triggered Vladimir Putin With One Word
Daniel Yergin was at the St. Petersburg International Economic Forum in 2013 when he got a daunting request: Could he…

Clever Leaves Reports First Quarter 2022 Results: Revenue Increases 50% To $5.2M

By Nicolás Jose Rodriguez

Clever Leaves Holdings Inc. (NASDAQ:CLVR) (NASDAQ:CLVRW), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids reported late Thursday its financial and operating results for the first quarter ended March 31, 2022.

First Quarter 2022 Summary vs. Same Year-Ago Quarter

  • Revenue increased 50% to $5.2 million compared to $3.5 million. Cannabinoid revenue increased 195% to $2.0 million compared to $0.7 million, and non-cannabinoid revenue increased 15% to $3.2 million compared to $2.8 million.
  • All-in cost per gram of dry flower increased to $0.35 compared to $0.16. The change in cost was attributed to the ramping of pre-commercial operating expenses ahead of expected revenue at the Company’s recently completed greenhouse expansion and post-harvest facility in Portugal.
  • Gross profit was $2.0 million, which includes a $0.8 million inventory write-down, compared to $2.1 million, which includes a $0.2 million inventory write-down.
  • Adjusted gross profit (a non-GAAP financial measure), which excludes such inventory write-down, increased 25% to $2.9 million compared to $2.3 million.
  • The gross margin, which includes such inventory write-down of $0.8 million, was 39.0% compared to 61.5%. Adjusted gross margin (a non-GAAP financial measure defined and reconciled herein), which excludes such inventory write-down, was 55.2% compared to 66.4%.
  • Net loss in the first quarter of 2022 increased to $16.1 million compared to $13.8 million for the same period in 2021, driven primarily by a $4.0 million restructuring expense, offset by an increase in loss due to a $1.7 million debt discount write off and loss on debt extinguishment of $2.3 million due to extinguishment of debt as offset by a gain on remeasurement of warrant liability.
  • Adjusted EBITDA  was $(6.7) million compared to $(5.5) million predominantly due to increased cost of sales including an inventory write-down and nominally higher R&D expense related to positioning for Colombian dried flower export as well as sales and marketing expenses.
  • Cash, cash equivalents, and restricted cash increased to $44.8 million on March 31, 2022, compared to $37.7 million on December 31, 2021. The increase was attributable to net proceeds raised from the Company’s at-the-market stock offering during the quarter.

Comments From Management

“Our revenue increased 50% year-over-year to $5.2 million, reflecting robust growth in our cannabinoid revenues across our target markets, as well as continued performance strength in our nutraceuticals business,” said Andres Fajardo, CEO of Clever Leaves in a press release.

“After narrowing our 2022 commercial focus to a core group of key markets—comprising Australia, Germany, Brazil, Israel, and the U.S.—we have already made solid progress activating and expanding our existing agreements, as well as adding new partnerships and growth initiatives, in those markets,” continued Fajardo.

Fajardo noted Clever expanded its distribution pathways in the U.S. and Germany by forming a research-oriented partnership with Biom Therapeutics in the U.S., becoming a fully-licensed medical cannabis distributor in Germany.

‘Aggressive Actions’

Clever completed a global workforce reduction. This reduction is expected to generate cash savings of $2.0 million in 2022 and $4.0 million in subsequent years. “We took aggressive actions to improve our balance sheet and our underlying cost structure, which we expect will yield cash savings in excess of $4.0 million per year. These initiatives allow us to operate from a leaner foundation as we strengthen our distribution network and capabilities,” Fajardo stated.

Reiterated 2022 Outlook and Strategic Growth Objectives

Based on current commercial momentum across its target markets, Clever Leaves reaffirms full-year 2022 revenue to be within the range of $20 million and $25 million, with adjusted gross margin expected to range between 50% and 55%.

The Company also expects adjusted EBITDA to range between $23 million and $20 million. In addition, Clever Leaves expects approximately $2 million to $3 million of annual capital expenditures.

Photo by Matteo Paganelli on Unsplash. 

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
IM Cannabis Reports Record First Quarter 2022 Financial Results, Revenues Increase 169% YoY To $23.6M
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), a medical and adult-use cannabis company with operations in Israel, Canada, and Germany,…
TerrAscend Reports First Quarter 2022 Financial Results, Net Sales Up To $49.7M
TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF), reported its financial results late Thursday for the first quarter ending March 31, 2022.
Organigram Q2 Fiscal 2022 Revenue Grows 117% YoY Primaraly Because Of This
Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI), the parent company of Organigram Inc., released its results for the second quarter ended…
Aurora Cannabis Reports Fiscal 2022 Q3 Results, Net Revenue $50.4M
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a Canadian cannabis company, announced its financial and operational results late Thursday for the…
One subscription that gives you access to news from hundreds of sites
MariMed Reports Strong Q1, Provides 2022 Financial Guidance
MariMed, Inc. (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results…
Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?
Aurora Cannabis Inc. (NASDAQ: ACB) reported financial and operational results late Thursday for the third quarter of fiscal 2022 ended March…
Get all your news in one place